Targeting LSD1 to prevent early oral cancers from getting worse
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy
['FUNDING_R01'] · BOSTON UNIVERSITY MEDICAL CAMPUS · NIH-11301858
Seeing if blocking a protein called LSD1 can stop precancerous mouth lesions and early oral cancers from becoming invasive.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY MEDICAL CAMPUS (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11301858 on ClinicalTrials.gov |
What this research studies
This work looks at how the protein LSD1 helps mouth cells progress from precancerous changes to invasive oral squamous cell carcinoma. Researchers use lab methods and animal models and are testing a topical LSD1 blocker applied during dysplasia to prevent progression. They are mapping which cells are affected and how LSD1 connects to inflammatory and immune signals, and are testing combinations with YAP inhibitors or anti‑PD‑1/PD‑L1 treatments. The goal is to develop targeted or topical options that could keep early lesions from turning into full-blown cancer.
Who could benefit from this research
Good fit: People with precancerous oral lesions (dysplasia) or early-stage oral squamous cell carcinoma, especially on the tongue, are the most likely candidates to benefit from this work.
Not a fit: Patients with advanced, widely metastatic oral cancer or tumors that do not depend on LSD1-related pathways are less likely to receive direct benefit.
Why it matters
Potential benefit: Could lead to topical or combination treatments that stop precancerous mouth lesions from becoming invasive and improve response to immunotherapy.
How similar studies have performed: Preclinical animal and laboratory studies have shown promising prevention and sensitization effects with LSD1 inhibition, but this approach has not yet been tested in people.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY MEDICAL CAMPUS — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BAIS, MANISH — BOSTON UNIVERSITY MEDICAL CAMPUS
- Study coordinator: BAIS, MANISH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.